Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
SUPN 
Supernus Pharmaceuticals Inc (SUPN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/20/2025: SUPN (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
5 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $39
1 Year Target Price $39
| 2 | Strong Buy |
| 0 | Buy |
| 3 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 2.8% | Avg. Invested days 50 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/20/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.76B USD | Price to earnings Ratio 28.4 | 1Y Target Price 39 |
Price to earnings Ratio 28.4 | 1Y Target Price 39 | ||
Volume (30-day avg) 5 | Beta 0.71 | 52 Weeks Range 25.55 - 40.28 | Updated Date 06/30/2025 |
52 Weeks Range 25.55 - 40.28 | Updated Date 06/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 1.11 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 9.27% | Operating Margin (TTM) -4.67% |
Management Effectiveness
Return on Assets (TTM) 2.76% | Return on Equity (TTM) 6.32% |
Valuation
Trailing PE 28.4 | Forward PE 20.16 | Enterprise Value 1334347761 | Price to Sales(TTM) 2.64 |
Enterprise Value 1334347761 | Price to Sales(TTM) 2.64 | ||
Enterprise Value to Revenue 2 | Enterprise Value to EBITDA 7.43 | Shares Outstanding 55989600 | Shares Floating 49274788 |
Shares Outstanding 55989600 | Shares Floating 49274788 | ||
Percent Insiders 4.87 | Percent Institutions 109.18 |
Analyst Ratings
Rating 3 | Target Price 39 | Buy - | Strong Buy 2 |
Buy - | Strong Buy 2 | ||
Hold 3 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Supernus Pharmaceuticals Inc
Company Overview
History and Background
Supernus Pharmaceuticals Inc. was founded in 2005. It is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases.
Core Business Areas
- Neurology: Development and commercialization of treatments for neurological disorders such as epilepsy, migraine, and Parkinson's disease.
- Psychiatry: Development and commercialization of treatments for psychiatric disorders, including ADHD.
Leadership and Structure
The leadership team includes Jack Khattar (President and CEO). The company has a typical organizational structure for a biopharmaceutical firm, with departments focused on research and development, clinical trials, regulatory affairs, manufacturing, and commercialization.
Top Products and Market Share
Key Offerings
- Oxtellar XR: Oxtellar XR is an extended-release formulation of oxcarbazepine approved for the treatment of partial seizures in adults and children. Competitors include generic oxcarbazepine formulations. Revenue data is available in company financial reports.
- Trokendi XR: Trokendi XR is an extended-release formulation of topiramate approved for the treatment of epilepsy and migraine. Competitors include generic topiramate and other migraine/epilepsy medications. Revenue data is available in company financial reports.
- Qelbree: Qelbree is a non-stimulant medication for ADHD in children, adolescents, and adults. Competitors include stimulant medications like Adderall and Concerta, and other non-stimulant options. Revenue data is available in company financial reports.
- Apadaz: Apadaz is a controlled substance medication for acute pain. The competitors include opioid pain medications. Revenue data is available in company financial reports.
- Xelstrym: Xelstrym is a dextroamphetamine transdermal system for the treatment of ADHD. The competitors include amphetamine medications like Adderall and Concerta.
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high research and development costs, lengthy regulatory approval processes, and intense competition. It continues to grow driven by innovation and an aging population.
Positioning
Supernus Pharmaceuticals Inc. focuses on CNS disorders. Its competitive advantages include its expertise in extended-release formulations and its focus on developing treatments for underserved patient populations.
Total Addressable Market (TAM)
The TAM for CNS disorders is substantial. Supernus is positioned to capture a portion of this market through its pipeline and existing product portfolio.
Upturn SWOT Analysis
Strengths
- Focus on CNS disorders
- Expertise in extended-release formulations
- Diversified product portfolio
- Experienced management team
Weaknesses
- Dependence on a limited number of key products
- Exposure to generic competition
- High R&D costs
- Reliance on successful clinical trials and regulatory approvals
Opportunities
- Expansion into new CNS indications
- Acquisition of complementary products or companies
- Geographic expansion
- Strategic partnerships
Threats
- Generic competition
- Regulatory hurdles
- Clinical trial failures
- Economic downturns
Competitors and Market Share
Key Competitors
- TEVA
- VTRS
- ALNY
- JAZZ
- GWPH
Competitive Landscape
Supernus faces competition from both generic and branded pharmaceutical companies. Its competitive advantages include its focus on CNS disorders and its expertise in extended-release formulations. Its key disadvantage is that they are smaller than many of the competitors in the space.
Major Acquisitions
Bimopharm
- Year: 2020
- Acquisition Price (USD millions): 300
- Strategic Rationale: Expanded the company's pipeline with novel therapies for CNS disorders.
Kadiria
- Year: 2023
- Acquisition Price (USD millions): 53.4
- Strategic Rationale: Provided access to an established sales force for the company's ADHD products. It also diversified the companies drug offerings
Growth Trajectory and Initiatives
Historical Growth: The historical growth of Supernus Pharmaceuticals Inc. has been driven by the commercial success of its key products.
Future Projections: Analyst estimates for Supernus Pharmaceuticals Inc.'s future growth are available from financial news and data providers.
Recent Initiatives: Recent strategic initiatives may include new product launches, acquisitions, or partnerships.
Summary
Supernus Pharmaceuticals is a growing biopharmaceutical company focused on CNS disorders with expertise in extended-release formulations. The company faces threats from generic competition and clinical trial risks. Qelbree sales are strong and could continue to improve profitability. Expansion into new indications and strategic partnerships can drive future growth.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Supernus Pharmaceuticals Inc. Investor Relations
- SEC Filings (10-K, 10-Q)
- Yahoo Finance
- Company Press Releases
- Analyst Reports
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Market share data and financial metrics may be approximate or based on estimates. Investment decisions should be based on thorough research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Supernus Pharmaceuticals Inc
Exchange NASDAQ | Headquaters Rockville, MD, United States | ||
IPO Launch date 2012-05-01 | Founder, President, CEO, Secretary & Director Mr. Jack A. Khattar M.B.A. | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 674 | Website https://www.supernus.com |
Full time employees 674 | Website https://www.supernus.com | ||
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes products for the treatment of central nervous system (CNS) diseases in the United States. The company offers Qelbree, a non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD); GOCOVRI for the treatment of dyskinesia and levodopa/carbidopa in patients with Parkinson's Disease (PD); Oxtellar XR, an extended-release oxcarbazepine product indicated for the monotherapy treatment of partial onset epilepsy seizures; and APOKYN for the acute and intermittent treatment of hypomobility or off episodes in patients with advanced PD. It also provides Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; XADAGO for the treatment of levodopa/carbidopa in patients with PD experiencing off episodes; and MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and chronic sialorrhea. In addition, the company develops ONAPGO, which received FDA approval, for the treatment of motor fluctuations in adults with advanced PD; SPN-817, a first-in-class selective acetylcholinesterase inhibitor, which is in Phase 2 clinical trial, for the treatment of epilepsy, partial seizures, Dravet syndrome, and Lennox-Gaustaut syndrome; SPN-820, a small molecule in Phase 2 clinical trial for treating resistant depression; SPN-443, a stimulant in Phase 1 trial for the treatment of ADHD/CNS; and SPN-446, a preclinical product for CNS. It markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. It has a development agreement with Navitor Inc. for the conduct of Phase 2 clinical program of SPN-820. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is based in Rockville, Maryland.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.